Literature DB >> 27357254

Autoimmunity: Do IgM antibodies protect against atherosclerosis in SLE?

Maureen McMahon1, Brian Skaggs1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27357254      PMCID： PMC6152880          DOI： 10.1038/nrrheum.2016.108

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

Review 1.  Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus.

Authors:  Zev Sthoeger; Amir Sharabi; Edna Mozes
Journal:  J Autoimmun       Date:  2014-06-21       Impact factor: 7.094

2.  IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms.

Authors:  Mizanur Rahman; Sudhir Sing; Zahra Golabkesh; Roland Fiskesund; Thomas Gustafsson; Tomas Jogestrand; Anna G Frostegård; Ingiäld Hafström; Anquan Liu; Johan Frostegård
Journal:  Clin Immunol       Date:  2016-04-19       Impact factor: 3.969

Review 3.  Protective Autoimmunity: A Unifying Model for the Immune Network Involved in CNS Repair.

Authors:  Michal Schwartz; Catarina Raposo
Journal:  Neuroscientist       Date:  2014-01-06       Impact factor: 7.519

4.  IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE.

Authors:  Caroline Grönwall; Ehtisham Akhter; Cheongeun Oh; Rufus W Burlingame; Michelle Petri; Gregg J Silverman
Journal:  Clin Immunol       Date:  2012-01-14       Impact factor: 3.969

5.  Low levels of antibodies against phosphorylcholine predict development of stroke in a population-based study from northern Sweden.

Authors:  Roland Fiskesund; Birgitta Stegmayr; Göran Hallmans; Max Vikström; Lars Weinehall; Ulf de Faire; Johan Frostegård
Journal:  Stroke       Date:  2010-02-11       Impact factor: 7.914

6.  Naturally occurring autoantibodies to apoptotic cells.

Authors:  Keith B Elkon; Gregg J Silverman
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

7.  Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans.

Authors:  Meng-Yun Chou; Linda Fogelstrand; Karsten Hartvigsen; Lotte F Hansen; Douglas Woelkers; Peter X Shaw; Jeomil Choi; Thomas Perkmann; Fredrik Bäckhed; Yury I Miller; Sohvi Hörkkö; Maripat Corr; Joseph L Witztum; Christoph J Binder
Journal:  J Clin Invest       Date:  2009-04-13       Impact factor: 14.808

Review 8.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

9.  IgM phosphorylcholine antibodies inhibit cell death and constitute a strong protection marker for atherosclerosis development, particularly in combination with other auto-antibodies against modified LDL.

Authors:  Roland Fiskesund; Jun Su; Ivana Bulatovic; Max Vikström; Ulf de Faire; Johan Frostegård
Journal:  Results Immunol       Date:  2012-01-08

10.  Increased prevalence of vulnerable atherosclerotic plaques and low levels of natural IgM antibodies against phosphorylcholine in patients with systemic lupus erythematosus.

Authors:  Cristina Anania; Thomas Gustafsson; Xiang Hua; Jun Su; Max Vikström; Ulf de Faire; Mikael Heimbürger; Tomas Jogestrand; Johan Frostegård
Journal:  Arthritis Res Ther       Date:  2010-11-23       Impact factor: 5.156
  10 in total
  5 in total

1.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

2.  In Schizophrenia, Deficits in Natural IgM Isotype Antibodies Including those Directed to Malondialdehyde and Azelaic Acid Strongly Predict Negative Symptoms, Neurocognitive Impairments, and the Deficit Syndrome.

Authors:  Michael Maes; Buranee Kanchanatawan; Sunee Sirivichayakul; André F Carvalho
Journal:  Mol Neurobiol       Date:  2018-11-27       Impact factor: 5.590

3.  Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds.

Authors:  Divya Thiagarajan; Anna G Frostegård; Sudhir Singh; Mizanur Rahman; Anquan Liu; Max Vikström; Karin Leander; Bruna Gigante; Mai-Lis Hellenius; Bo Zhang; Roman A Zubarev; Ulf de Faire; Susanna L Lundström; Johan Frostegård
Journal:  J Am Heart Assoc       Date:  2016-12-20       Impact factor: 5.501

4.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

5.  Relationship between natural and infection-induced antibodies in systemic autoimmune diseases (SAD): SLE, SSc and RA.

Authors:  K Böröcz; D Simon; S Erdő-Bonyár; K T Kovács; É Tuba; L Czirják; P Németh; T Berki
Journal:  Clin Exp Immunol       Date:  2020-10-13       Impact factor: 4.330
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.